Literature DB >> 11117919

Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms.

F Van den Bosch, E Kruithof, M De Vos, F De Keyser, H Mielants.   

Abstract

Four patients with Crohn's disease and spondyloarthropathy were treated with infliximab for treatment-resistant gut inflammation. A substantial improvement in gastrointestinal signs and symptoms was noted, which was accompanied by a rapid reduction in C-reactive protein concentrations. Moreover, all four patients had a significant improvement of axial manifestations and/or peripheral arthritis, related to their spondyloarthropathy. This fast and substantial improvement of the articular manifestations of Crohn's disease after infliximab treatment warrants further investigation of the therapeutic potential of TNF-alpha blockade in other subtypes of spondyloarthropathies.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11117919     DOI： 10.1016/s0140-6736(00)03239-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  50 in total

1.  Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up.

Authors:  E Kruithof; F Van den Bosch; D Baeten; A Herssens; F De Keyser; H Mielants; E M Veys
Journal:  Ann Rheum Dis       Date:  2002-03       Impact factor: 19.103

Review 2.  Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alpha.

Authors:  F Van den Bosch; D Baeten; E Kruithof; F De Keyser; H Mielants; E M Veys
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

Review 3.  Extraintestinal complications of inflammatory bowel disease.

Authors:  Tim Orchard
Journal:  Curr Gastroenterol Rep       Date:  2003-12

4.  Anti-saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy.

Authors:  I E A Hoffman; P Demetter; M Peeters; M De Vos; H Mielants; E M Veys; F De Keyser
Journal:  Ann Rheum Dis       Date:  2003-05       Impact factor: 19.103

Review 5.  Management of arthropathy in inflammatory bowel diseases.

Authors:  Rosario Peluso; Francesco Manguso; Maria Vitiello; Salvatore Iervolino; Matteo Nicola Dario Di Minno
Journal:  Ther Adv Chronic Dis       Date:  2015-03       Impact factor: 5.091

6.  Infliximab as a treatment for systemic amyloidosis associated with Crohn's disease.

Authors:  M Iizuka; S Konno; Y Horie; H Itou; K Shindo; S Watanabe
Journal:  Gut       Date:  2006-05       Impact factor: 23.059

Review 7.  Conventional therapy for Crohn's disease.

Authors:  Carsten Büning; Herbert Lochs
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

8.  Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan.

Authors:  Fumiaki Ueno; Toshiyuki Matsui; Takayuki Matsumoto; Katsuyoshi Matsuoka; Mamoru Watanabe; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2012-10-23       Impact factor: 7.527

9.  [Update: enterogenic spondylarthritis].

Authors:  Elisabeth Märker-Hermann
Journal:  Z Rheumatol       Date:  2021-05-27       Impact factor: 1.372

10.  A survey of European and Canadian rheumatologists regarding the treatment of patients with ankylosing spondylitis and extra-articular manifestations.

Authors:  Filip Van den Bosch
Journal:  Clin Rheumatol       Date:  2009-12-03       Impact factor: 2.980
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.